174 related articles for article (PubMed ID: 33399078)
41. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Klanova M; Sehn LH; Bence-Bruckler I; Cavallo F; Jin J; Martelli M; Stewart D; Vitolo U; Zaja F; Zhang Q; Mattiello F; Sellam G; Punnoose EA; Szafer-Glusman E; Bolen CR; Oestergaard MZ; Fingerle-Rowson GR; Nielsen T; Trneny M
Blood; 2019 Feb; 133(9):919-926. PubMed ID: 30617197
[TBL] [Abstract][Full Text] [Related]
42. A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.
Brandt A; Matschke J; Fehrle W; von Wenserski L; Bokemeyer C; Illerhaus G; Binder M
Leuk Lymphoma; 2019 Feb; 60(2):334-340. PubMed ID: 30033830
[TBL] [Abstract][Full Text] [Related]
43. Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma.
Zhang W; Huang C; Liu R; Zhang H; Li W; Yin S; Wang L; Liu W; Liu L
Front Immunol; 2022; 13():983934. PubMed ID: 36275715
[TBL] [Abstract][Full Text] [Related]
44. Testicular Relapse of Primary Diffuse Large B-cell Lymphoma of the Central Nervous System - a Rare Occurrence.
Ollila TA; Kishkovich TP; Olszewski AJ; Patel NR; Jackson C; Roussel B; Niroula R; Treaba DO
R I Med J (2013); 2023 Mar; 106(2):8-12. PubMed ID: 36848533
[TBL] [Abstract][Full Text] [Related]
45. Genomic characterization of primary central nervous system lymphoma.
Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
[TBL] [Abstract][Full Text] [Related]
46. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.
Simard J; Roschewski M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):709-717. PubMed ID: 35787364
[TBL] [Abstract][Full Text] [Related]
47. High frequency of inactivating tetraspanin
Elfrink S; de Winde CM; van den Brand M; Berendsen M; Roemer MGM; Arnold F; Janssen L; van der Schaaf A; Jansen E; Groenen PJTA; Eijkelenboom A; Stevens W; Hess CJ; van Krieken JH; Vermaat JSP; Cleven AHG; de Groen RAL; Neviani V; de Jong D; van Deventer S; Scheijen B; van Spriel AB
Blood; 2019 Sep; 134(12):946-950. PubMed ID: 31366619
[TBL] [Abstract][Full Text] [Related]
48. Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.
Barranco GI; Fernández S; Oña R; González-Rincón J; Martínez-Ramírez A; Teijo A; Camacho FI; Pinedo FJ; Sánchez-Beato M; Pedrosa L; de la Fuente A; Estévez M; Iglesias R; Montalbán C; García JF
Haematologica; 2019 Jul; 104(7):e326-e329. PubMed ID: 30890596
[No Abstract] [Full Text] [Related]
49. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
50. Prediction of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Using Pretherapeutic [18F]2-Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography/Computed Tomography.
Song YS; Lee WW; Lee JS; Kim SE
Medicine (Baltimore); 2015 Nov; 94(44):e1978. PubMed ID: 26554808
[TBL] [Abstract][Full Text] [Related]
51. How I treat secondary CNS involvement by aggressive lymphomas.
Alderuccio JP; Nayak L; Cwynarski K
Blood; 2023 Nov; 142(21):1771-1783. PubMed ID: 37702537
[TBL] [Abstract][Full Text] [Related]
52. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
53. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM; Ribera JM;
Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
[TBL] [Abstract][Full Text] [Related]
54. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
55. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
[TBL] [Abstract][Full Text] [Related]
56. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.
Qualls D; Abramson JS
Haematologica; 2019 Jan; 104(1):25-34. PubMed ID: 30573511
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of clonal diversity of immunoglobulin gene rearrangements in patients with diffuse large B-cell lymphoma.
Yang MH; Yen CC; Chiang SC; Bai LY; Lee KD; Hsiao LT; Chao TC; Wang WS; Liu JH; Chiou TJ; Chen PM
Oncol Rep; 2005 Mar; 13(3):503-8. PubMed ID: 15706425
[TBL] [Abstract][Full Text] [Related]
58. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
59. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
